DB18976ApprovedProtein Based Therapies
Veligrotug is a humanized IgG1 monoclonal antibody and IGF-1R inhibitor indicated to treat proptosis and diplopia in thyroid eye disease regardless of activity or duration. Veligrotug is a humanized IgG1 monoclonal antibody that binds the insulin-like growth factor-1 receptor and blocks ligand-induced receptor autophosphorylation, interrupting IGF-1R signaling.
- Mechanism
- Curator reviewed
Pharmacologically active on Insulin-like growth factor 1 receptor
- Primary indication
- Veligrotug is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.Curator reviewed · 1 structured indication
- First approval
- United States, 2026
- Also known as
- Anti-cd122 monoclonal antibody ave1642 · Anti-igf-1r monoclonal antibody ave1642 · Immunoglobulin G1-kappa, anti-[Homo sapiens IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221)], chimeric monoclonal antibody (gamma1 heavy chain chimeric (1-454) [VH (Mus musculus IGHV1S81*02 (91.8%) -(IGHD) -IGHJ1*01 (93.8%), CDR-IMGT · Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human-Mus musculus monoclonal VRDN-001 γ1-chain), disulfide with human-Mus musculus monoclonal VRDN-001 κ-chain, dimer · Veligrotug-vvze
- Code names
- AVE-1642 · VRDN-001
- Brand names
Resolves to
Compound
Clinical / RWD
Targets
What you can answer from here — as of August 26, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Veligrotug, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account